

# Hyo Song Kim

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2694394/hyo-song-kim-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

92  
papers

1,872  
citations

27  
h-index

39  
g-index

96  
ext. papers

2,171  
ext. citations

3.8  
avg. IF

4.06  
L-index

#	Paper	IF	Citations
92	PD-L1 tumour expression is predictive of pazopanib response in soft tissue sarcoma. <i>BMC Cancer</i> , <b>2021</b> , 21, 336	4.8	1
91	Clinicopathological features of 70 desmoid-type fibromatoses confirmed by E-catenin immunohistochemical staining and CTNNB1 mutation analysis. <i>PLoS ONE</i> , <b>2021</b> , 16, e0250619	3.7	1
90	Detection of asymptomatic recurrence improves survival of gastric cancer patients. <i>Cancer Medicine</i> , <b>2021</b> , 10, 3249-3260	4.8	0
89	Prognostic implications of PD-L1 expression in patients with angiosarcoma. <i>Future Science OA</i> , <b>2021</b> , 7, FSO691	2.7	2
88	Pemetrexed plus cisplatin in patients with previously treated advanced sarcoma: a multicenter, single-arm, phase II trial. <i>ESMO Open</i> , <b>2021</b> , 6, 100249	6	0
87	Real-World Outcomes of Pazopanib Treatment in Korean Patients with Advanced Soft Tissue Sarcoma: A Multicenter Retrospective Cohort Study. <i>Targeted Oncology</i> , <b>2020</b> , 15, 485-493	5	1
86	Comprehensive Immuno-Molecular Profiles for Liposarcoma: Roles of Programmed Death Ligand 1, Microsatellite Instability, and PIK3CA. <i>Oncology</i> , <b>2020</b> , 98, 817-826	3.6	3
85	Phase 2 study of afatinib among patients with recurrent and/or metastatic esophageal squamous cell carcinoma. <i>Cancer</i> , <b>2020</b> , 126, 4521-4531	6.4	3
84	S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial. <i>Cancer Research and Treatment</i> , <b>2019</b> , 51, 1-11	5.2	13
83	Randomised phase II trial comparing four front-line doublets in Asian patients with metastatic gastric cancer. <i>European Journal of Cancer</i> , <b>2019</b> , 112, 20-28	7.5	0
82	Clinical analysis of patients with skeletal metastasis of lung cancer. <i>BMC Cancer</i> , <b>2019</b> , 19, 303	4.8	25
81	Phase II trial of preoperative sequential chemotherapy followed by chemoradiotherapy for high-risk gastric cancer. <i>Radiotherapy and Oncology</i> , <b>2019</b> , 140, 143-149	5.3	3
80	Immunohistochemistry Biomarkers Predict Survival in Stage II/III Gastric Cancer Patients: From a Prospective Clinical Trial. <i>Cancer Research and Treatment</i> , <b>2019</b> , 51, 819-831	5.2	8
79	Differences in the Efficacies of Pazopanib and Gemcitabine/Docetaxel as Second-Line Treatments for Metastatic Soft Tissue Sarcoma. <i>Oncology</i> , <b>2019</b> , 96, 59-69	3.6	9
78	The prognostic value of volume-based parameters using F-FDG PET/CT in gastric cancer according to HER2 status. <i>Gastric Cancer</i> , <b>2018</b> , 21, 213-224	7.6	14
77	Marked Loss of Muscle, Visceral Fat, or Subcutaneous Fat After Gastrectomy Predicts Poor Survival in Advanced Gastric Cancer: Single-Center Study from the CLASSIC Trial. <i>Annals of Surgical Oncology</i> , <b>2018</b> , 25, 3222-3230	3.1	40
76	Prognostic implications of polycomb proteins ezh2, suz12, and eed1 and histone modification by H3K27me3 in sarcoma. <i>BMC Cancer</i> , <b>2018</b> , 18, 158	4.8	12

75	Prognostic significance of preoperative CT findings in patients with advanced gastric cancer who underwent curative gastrectomy. <i>PLoS ONE</i> , <b>2018</b> , 13, e0202207	3.7	5
74	Retrospective analysis of palliative chemotherapy for the patients with bladder adenocarcinoma: Korean Cancer Study Group Genitourinary and Gynecology Cancer Committee. <i>Korean Journal of Internal Medicine</i> , <b>2018</b> , 33, 383-390	2.5	7
73	Patterns of Care for Radiotherapy in the Neoadjuvant and Adjuvant Treatment of Gastric Cancer: A Twelve-Year Nationwide Cohort Study in Korea. <i>Cancer Research and Treatment</i> , <b>2018</b> , 50, 118-128	5.2	5
72	Multidisciplinary treatment for patients with stage IV gastric cancer: the role of conversion surgery following chemotherapy. <i>BMC Cancer</i> , <b>2018</b> , 18, 1116	4.8	31
71	Efficacy of Postoperative Radiotherapy Using Modern Techniques in Patients with Retroperitoneal Soft Tissue Sarcoma. <i>Yonsei Medical Journal</i> , <b>2018</b> , 59, 1049-1056	3	5
70	A Prediction Model of Tumor Progression and Survival in HER2-Positive Metastatic Gastric Cancer Patients Treated with Trastuzumab and Chemotherapy. <i>AAPS Journal</i> , <b>2018</b> , 20, 72	3.7	
69	Different subtypes of epithelioid sarcoma and their clinical implication: long-term multi-institutional experience with a rare sarcoma. <i>Apmis</i> , <b>2017</b> , 125, 223-229	3.4	7
68	Reassessment of alkaline phosphatase as serum tumor marker with high specificity in osteosarcoma. <i>Cancer Medicine</i> , <b>2017</b> , 6, 1311-1322	4.8	30
67	Integration of radiotherapy and chemotherapy for abdominal lymph node recurrence in gastric cancer. <i>Clinical and Translational Oncology</i> , <b>2017</b> , 19, 1268-1275	3.6	4
66	Outcomes of Treatment for Malignant Peripheral Nerve Sheath Tumors: Different Clinical Features Associated with Neurofibromatosis Type 1. <i>Cancer Research and Treatment</i> , <b>2017</b> , 49, 717-726	5.2	23
65	Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer. <i>Oncotarget</i> , <b>2017</b> , 8, 61837-61845	6.1	10
64	Depth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumab. <i>Oncotarget</i> , <b>2017</b> , 8, 31169-31179	3.3	8
63	Complementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to select targeted therapy for advanced gastric cancer. <i>Oncotarget</i> , <b>2017</b> , 8, 38389-38398	3.3	7
62	A novel TP53-KPNA3 translocation defines a de novo treatment-resistant clone in osteosarcoma. <i>Journal of Physical Education and Sports Management</i> , <b>2016</b> , 2, a000992	2.8	11
61	Prognostic significance and frequency of EGFR expression and amplification in surgically resected advanced gastric cancer. <i>Japanese Journal of Clinical Oncology</i> , <b>2016</b> , 46, 507-16	2.8	9
60	Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography in patients with gastric neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma. <i>Annals of Nuclear Medicine</i> , <b>2016</b> , 30, 279-86	2.5	9
59	Receptor tyrosine kinase amplified gastric cancer: Clinicopathologic characteristics and proposed screening algorithm. <i>Oncotarget</i> , <b>2016</b> , 7, 72099-72112	3.3	11
58	Prognostic implications of PIK3CA amplification in curatively resected liposarcoma. <i>Oncotarget</i> , <b>2016</b> , 7, 24549-58	3.3	7

57	PIK3CA amplification is associated with poor prognosis among patients with curatively resected esophageal squamous cell carcinoma. <i>Oncotarget</i> , <b>2016</b> , 7, 30691-701	3.3	15
56	Efficacy and Toxicity of Mammalian Target Rapamycin Inhibitors in Patients with Metastatic Renal Cell Carcinoma with Renal Insufficiency: The Korean Cancer Study Group GU 14-08. <i>Cancer Research and Treatment</i> , <b>2016</b> , 48, 1286-1292	5.2	4
55	Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus. <i>Oncotarget</i> , <b>2016</b> , 7, 10547-56	3.3	44
54	Prognostic Model to Predict Survival Outcome for Curatively Resected Liposarcoma: A Multi-Institutional Experience. <i>Journal of Cancer</i> , <b>2016</b> , 7, 1174-80	4.5	22
53	A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology. <i>Cancer Research and Treatment</i> , <b>2016</b> , 48, 553-60	5.2	13
52	Comprehensive expression profiles of gastric cancer molecular subtypes by immunohistochemistry: implications for individualized therapy. <i>Oncotarget</i> , <b>2016</b> , 7, 44608-44620	3.3	31
51	Genetic alterations and their clinical implications in gastric cancer peritoneal carcinomatosis revealed by whole-exome sequencing of malignant ascites. <i>Oncotarget</i> , <b>2016</b> , 7, 8055-66	3.3	28
50	Cumulative Metformin Use and Its Impact on Survival in Gastric Cancer Patients After Gastrectomy. <i>Annals of Surgery</i> , <b>2016</b> , 263, 96-102	7.8	43
49	Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma. <i>BMC Cancer</i> , <b>2016</b> , 16, 434	4.8	93
48	Recursive partition analysis of peritoneal and systemic recurrence in patients with gastric cancer who underwent D2 gastrectomy: Implications for neoadjuvant therapy consideration. <i>Journal of Surgical Oncology</i> , <b>2016</b> , 114, 859-864	2.8	10
47	Multidisciplinary treatment of inferior vena cava leiomyosarcoma. <i>ANZ Journal of Surgery</i> , <b>2016</b> , 86, 104-5		1
46	The frequency and impact of FGFR1 amplification on clinical outcomes in Korean patients with small cell lung cancer. <i>Lung Cancer</i> , <b>2015</b> , 88, 325-31	5.9	7
45	Clinicopathological features and prognostic significance of HER2 expression in gastric cancer. <i>Oncology</i> , <b>2015</b> , 88, 147-56	3.6	14
44	PTEN deficiency as a predictive biomarker of resistance to HER2-targeted therapy in advanced gastric cancer. <i>Oncology</i> , <b>2015</b> , 88, 76-85	3.6	24
43	Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series. <i>BMC Cancer</i> , <b>2015</b> , 15, 154	4.8	46
42	Leiomyosarcoma: investigation of prognostic factors for risk-stratification model. <i>International Journal of Clinical Oncology</i> , <b>2015</b> , 20, 1226-32	4.2	7
41	Proper timing of adjuvant chemotherapy affects survival in patients with stage 2 and 3 gastric cancer. <i>Annals of Surgical Oncology</i> , <b>2015</b> , 22, 224-31	3.1	38
40	Current Strategy of Chemotherapy for Bone Tumors. <i>The Journal of the Korean Orthopaedic Association</i> , <b>2015</b> , 50, 438	0.1	

39	Incidence and Survival of Pediatric Soft Tissue Sarcomas: Comparison between Adults and Children. <i>Cancer Research and Treatment</i> , <b>2015</b> , 47, 9-17	5.2	7
38	Fibroblast growth factor receptor 1 gene amplification is associated with poor survival in patients with resected esophageal squamous cell carcinoma. <i>Oncotarget</i> , <b>2015</b> , 6, 2562-72	3.3	27
37	Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma. <i>Oncotarget</i> , <b>2015</b> , 6, 44971-84	3.3	10
36	Results of a Phase II Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Patients Who Failed First-Line Therapy Containing Dacarbazine. <i>Cancer Research and Treatment</i> , <b>2015</b> , 47, 781-9	5.2	7
35	Vascular soft-tissue sarcomas: a prognostic model from a retrospective single-center study. <i>Oncology</i> , <b>2014</b> , 86, 329-35	3.6	
34	Prognostic implications of anaplastic lymphoma kinase gene aberrations in rhabdomyosarcoma; an immunohistochemical and fluorescence in situ hybridisation study. <i>Journal of Clinical Pathology</i> , <b>2014</b> , 67, 33-9	3.9	11
33	Ifosfamide-induced Fanconi syndrome with diabetes insipidus. <i>Korean Journal of Internal Medicine</i> , <b>2014</b> , 29, 246-9	2.5	12
32	Clinical features and treatment of collecting duct carcinoma of the kidney from the Korean cancer study group genitourinary and gynecology cancer committee. <i>Cancer Research and Treatment</i> , <b>2014</b> , 46, 141-7	5.2	11
31	Randomized controlled trial of standardized education and telemonitoring for pain in outpatients with advanced solid tumors. <i>Supportive Care in Cancer</i> , <b>2013</b> , 21, 1751-9	3.9	27
30	Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2013</b> , 72, 825-35	3.5	53
29	Efficacy and safety of everolimus in Korean patients with metastatic renal cell carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2013</b> , 72, 853-60	3.5	5
28	Therapeutic strategies for well-differentiated papillary mesothelioma of the peritoneum. <i>Japanese Journal of Clinical Oncology</i> , <b>2013</b> , 43, 996-1003	2.8	23
27	A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer. <i>European Journal of Cancer</i> , <b>2012</b> , 48, 518-26	7.5	98
26	The efficacy and toxicity of S-1 and cisplatin as first-line chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2012</b> , 70, 539-46	3.5	3
25	Weekly gemcitabine and docetaxel in refractory soft tissue sarcoma: a retrospective analysis. <i>Cancer Research and Treatment</i> , <b>2012</b> , 44, 43-9	5.2	13
24	Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2011</b> , 68, 991-9	3.5	4
23	A prognostic model to predict clinical outcome in gastric cancer patients with bone metastasis. <i>Oncology</i> , <b>2011</b> , 80, 142-50	3.6	32
22	Sunitinib for Asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles. <i>Oncology</i> , <b>2011</b> , 80, 395-405	3.6	45

21	Advanced detection of recent changing trends in gastric cancer survival: up-to-date comparison by period analysis. <i>Japanese Journal of Clinical Oncology</i> , <b>2011</b> , 41, 1344-50	2.8	13
20	Excision repair cross-complementation group 1 (ERCC1) expression in advanced urothelial carcinoma patients receiving cisplatin-based chemotherapy. <i>Apmis</i> , <b>2010</b> , 118, 941-8	3.4	34
19	Molecular biomarkers for advanced renal cell carcinoma: implications for prognosis and therapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2010</b> , 28, 157-63	2.8	12
18	Definitive chemoradiation therapy with capecitabine in locally advanced pancreatic cancer. <i>Anti-Cancer Drugs</i> , <b>2010</b> , 21, 107-12	2.4	5
17	The clinical outcome of chemotherapy-induced amenorrhea in premenopausal young patients with breast cancer with long-term follow-up. <i>Annals of Surgical Oncology</i> , <b>2010</b> , 17, 3259-68	3.1	38
16	Noncutaneous malignant melanoma: a prognostic model from a retrospective multicenter study. <i>BMC Cancer</i> , <b>2010</b> , 10, 167	4.8	42
15	Novel sunitinib strategy in metastatic renal cell carcinoma on hemodialysis: intermittent dose of sunitinib after hemodialysis. <i>Cancer Research and Treatment</i> , <b>2010</b> , 42, 180-4	5.2	9
14	Clinicopathologic features of metachronous or synchronous gastric cancer patients with three or more primary sites. <i>Cancer Research and Treatment</i> , <b>2010</b> , 42, 217-24	5.2	20
13	Comparison of survival in advanced non-small cell lung cancer patients in the pre- and post-gefitinib eras. <i>Oncology</i> , <b>2009</b> , 76, 239-46	3.6	15
12	A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer. <i>BMC Cancer</i> , <b>2009</b> , 9, 110	4.8	30
11	Liposarcoma: exploration of clinical prognostic factors for risk based stratification of therapy. <i>BMC Cancer</i> , <b>2009</b> , 9, 205	4.8	37
10	Clinical significance of a serum CA15-3 surge and the usefulness of CA15-3 kinetics in monitoring chemotherapy response in patients with metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2009</b> , 118, 89-97	4.4	32
9	Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2009</b> , 63, 1141-5	3.5	51
8	Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2009</b> , 64, 917-24	3.5	3
7	L1 cell adhesion molecule as a predictor for recurrence in pulmonary carcinoids and large-cell neuroendocrine tumors. <i>Apmis</i> , <b>2009</b> , 117, 140-6	3.4	12
6	Whole blood Epstein-Barr virus DNA load as a diagnostic and prognostic surrogate: extranodal natural killer/T-cell lymphoma. <i>Leukemia and Lymphoma</i> , <b>2009</b> , 50, 757-63	1.9	51
5	Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2009</b> , 4, 809-15	8.9	127
4	Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea. <i>Cancer Research and Treatment</i> , <b>2009</b> , 41, 67-72	5.2	57

- 3 A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma. *Cancer Chemotherapy and Pharmacology*, **2008**, 62, 77-84<sup>2.5</sup> 34
- 2 Clinical outcome of gastric cancer patients with bone marrow metastases. *Oncology*, **2007**, 73, 192-7 3.6 72
- 1 Catecholamine cardiomyopathy associated with paraganglioma rescued by percutaneous cardiopulmonary support: inverted Takotsubo contractile pattern. *Circulation Journal*, **2007**, 71, 1993-5<sup>2.9</sup> 25